GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aclaris Therapeutics Inc (LTS:0H8T) » Definitions » Accounts Payable

Aclaris Therapeutics (LTS:0H8T) Accounts Payable : $4.69 Mil (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Aclaris Therapeutics Accounts Payable?

Aclaris Therapeutics's Accounts Payable for the quarter that ended in Dec. 2024 was $4.69 Mil.

Aclaris Therapeutics's quarterly Accounts Payable increased from Jun. 2024 ($7.27 Mil) to Sep. 2024 ($7.66 Mil) but then declined from Sep. 2024 ($7.66 Mil) to Dec. 2024 ($4.69 Mil).

Aclaris Therapeutics's annual Accounts Payable declined from Dec. 2022 ($10.35 Mil) to Dec. 2023 ($8.88 Mil) and declined from Dec. 2023 ($8.88 Mil) to Dec. 2024 ($4.69 Mil).


Aclaris Therapeutics Accounts Payable Historical Data

The historical data trend for Aclaris Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclaris Therapeutics Accounts Payable Chart

Aclaris Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.25 9.99 10.35 8.88 4.69

Aclaris Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.88 10.81 7.27 7.66 4.69

Aclaris Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.


Aclaris Therapeutics Accounts Payable Related Terms

Thank you for viewing the detailed overview of Aclaris Therapeutics's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Aclaris Therapeutics Business Description

Traded in Other Exchanges
Address
701 Lee Road, Suite 103, Wayne, PA, USA, 19087
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Aclaris Therapeutics Headlines

No Headlines